Based on a recent third-party analysis conducted by the actuarial firm Accorded, Noom Med is expected to drive 4.1x ROI versus the most common alternative for employers who wish to cover GLP-1s for their workforce
While conclusive evidence is pending, the convergence of mechanistic, preclinical, and clinical data makes GLP-1 inhibitors one of the most promising emerging approaches to substance use disorders
And most importantly who is most likely to benefit from them
In April 2025, Northstrive Biosciences announced it received preliminary feedback from the FDA on its planned Type B pre-IND meeting, supporting the advancement of its EL-22 program in combination with GLP-1 receptor agonists toward a Phase 2 clinical trial
The retatrutide dosage guide covers the specific TRIUMPH-1 escalation protocol
Most people can expect 15-25% weight loss over one year if they reach therapeutic doses (8-12mg) and make concurrent lifestyle changes
